Hyal reports loss decreased by 24%

Article Abstract:

Canadian drug development firm Hyal Pharmaceutical Corp reported a loss of $14.1 million or 47 cents a share for 1998 versus a $18.6 million loss or 70 cents per share in 1997. Hyal also reported that research and development costs fell from $11.7 million in 1997 to $2.8 million in 1998. The lower R&D costs were attributed to lower clinical, preclinical and consulting expenses.

Sales, profits & dividends, Hyal Pharmaceutical Corp.

---

Drug approvals seen slowing

Article Abstract:

Toronto, Ont.-based Hemosol Inc., which is led by chief executive officer John Kennedy, has been stunned by the U.S. Food and Drug Administration's order that it halt development of its Hemolink product. The drug industry has become concerned over the FDA's decision to slow down the approval process of new drugs.

Product development, Government regulation (cont), United States, Laws, regulations and rules, Pharmaceutical industry, United States. Food and Drug Administration, Hemosol Inc.

---

Drug trial halt at YM sets stage for selloff

Article Abstract:

The decision of YM Biosciences Inc. to stop its trial of cancer drug tesmilifene and sell stocks following government concern over the safety of the drug is discussed.

Product standards, safety, & recalls, General services, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Securities issued, listed, Metabolic Agents NEC, Metabolic Agents, Safety and security measures, Product defects and recalls, Securities, Company securities, YM Biosciences Inc., Tesmilifene (Medication)

Similar abstracts:

• Abstracts: Where mice have roamed. Letting the thing speak for itself. Where mice fear to go
• Abstracts: More errors disclosed by A.T.&T. BellSouth taps experience for move into new services
• Abstracts: Royal Oak creditors challenge payment deal. Troubled Royal Oak heads back to court
• Abstracts: Toyota's Nakatani takes chairman role. Toyota Canada head set for return to Japan. Stronach decries Austrian 'smear camapaign'

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.